Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy

AIDS

Volumn 13, Issue 16, 1999, Pages 2261-2267

  Domingo, Pere ^a,b   Matias Guiu, Xavier ^a   Pujol, Ramón M ^a   Francia, Esther ^a   Lagarda, Elena ^a   Sambeat, María A ^a   Vázquez, Guillermo ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Adipocyte; Antiretroviral therapy; Apoptosis; HIV 1 protease inhibitor associated lipodystrophy; HIV 1 protease inhibitors; HIVinfection; Necrosis; Programmed cell death; Subcutaneous fat

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DIGOXIGENIN; DNA NUCLEOTIDYLEXOTRANSFERASE; LIPID; PROTEINASE INHIBITOR;

ADIPOCYTE; ADULT; ANGIOGENESIS; APOPTOSIS; ARTICLE; BIOPSY; BODY SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIPID BLOOD LEVEL; LIPODYSTROPHY; LIPOGRANULOMA; MALE; PATHOGENESIS; PRIORITY JOURNAL; SUBCUTANEOUS FAT; VIRUS LOAD;

ADIPOCYTES; ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; IN SITU NICK-END LABELING; LIPODYSTROPHY; MALE; MIDDLE AGED;

EID: 0042438992     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199911120-00008     Document Type: Article

References (28)

1. 1. Hetts SW. To die or not to die: an overview of apoptosis and its role in disease. JAMA 1998, 279:300-307.
2. 2. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993, 341:1251-1254.
3. 3. Mallat Z, Tedgui A, Fontalban F, Frank R, Durigo M, Fontaine G. Evidence of apoptosis in arrythmogenic right ventricular dysplasia. N Engl J Med 1996, 335:1190-1196.
4. 4. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996, 335:1182-1189.
5. 5. Prins JB, Walker NI, Winterford CM, Cameron DP. Human adipocyte apoptosis occurs in malignancy. Biochem Biophys Res Commun 1994, 205:625-630.
6. 6. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351:1881-1883.
7. 7. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
8. 8. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
9. 9. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definitio for AIDS among adolescents and adults. MMWR 1993, 41 (RR-17):1-13.
10. 10. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 in plasma: application to acute retroviral infection. J Clin Microbiol 1994, 32:292-300.
11. 11. Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Despres JP. A single threshold of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 1996, 64:685-693.
12. 12. Armitage P, Berry G. Statistical Methods in Medical Research. Oxford: Blackwell Scientific Publications; 1994.
13. 13. Colucci WS. Apoptosis in the heart. N Engl J Med 1996, 335:1224-1226.
14. 14. Zalla MJ, Winkelmann RK, Gluck OS. Involutional lipoatrophy: macrophage-related involution of fat lobules. Arch Dermatol 1995, 191:149-153.
15. 15. Corcoran C, Crinspoon S. Treatments for wasting in patients with the acquired immunodeficiency syndrome. N Engl J Med 1999, 340:1740-1750.
16. 16. Levy JA. Caution: should we be treating HIV infection early? Lancet 1998, 352:982-983.
17. 17. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998, 351:1328-1329.
18. 18. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998, 351:1958-1960.
19. 19. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998, 351:1959.
20. 20. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998, 351:1958-1959.
21. 21. Gagnon AM, Angel JB, Sorisky A. Protease inhibitors and adipocyte differentiation in cell culture. Lancet 1998, 352:1032.
22. 22. Qian H, Hausman GJ, Compton MM, Azain MJ, Hartzell DL, Baile CA. Leptin regulation of peroxisome proliferator-activated receptor-gamma, tumor necrosis factor, and uncoupling protein-2 expression in adipose tissues. Biochem Biophys Res Commun 1998, 246:660-667.
23. 23. Qian H, Azain MJ, Compton MM, Hartzell DL, Hausman GJ, Baile CA. Brain administration of leptin causes deletion of adipocytes by apoptosis. Endocrinology 1998, 139:791-794.
24. 24. Prins JB, Niesler CU, Winterford CM, et al. Tumor necrosis factor-a induces apoptosis of human adipose cells. Diabetes 1997, 46:1939-1944.
25. 25. Prins JB, O'Rahilly S. Regulation of adipose cell number in man. Clin Sci (Colch) 1997, 92:3-11.
26. 26. Niesler CU, Siddle K, Prins JB. Human preadipocytes display a depot-specific susceptibility to apoptosis. Diabetes 1998, 47:1365-1368.
27. 27. Montague CT, Prins JB, Sanders L, et al. Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 1998, 47:1384-1391.
28. 28. Chawla A, Lazar MA. Peroxisome proliferator and retinoid signaling pathways co-regulate preadipocyte phenotype and survival. Proc Natl Acad Sci USA 1994, 91:1786-1790.